21 March 2021 - Everest Medicines announced today that the China National Medical Products Administration has accepted its new drug application for Xerava (eravacycline) for the treatment of complicated intra-abdominal infections in patients in China.

Xerava is a novel, fully synthetic, broad-spectrum parenteral antibiotic of the tetracycline class. It was approved for the treatment of a complicated intra-abdominal infection in adults in Singapore in April 2020 and is currently approved for the treatment of complicated intra-abdominal infections in the US and EU.

Read Everest Medicines press release